Mankind Pharma · risk themes across the available quarters.
Bear-case history
Management admitted disappointment with organic domestic growth (6% vs historical 1.3x IPM outperformance). Sales force restructuring took longer than expected (12+ months vs 6-9 months targeted) as new representatives require time to build doctor relationships in tier 2-4 markets.
EBITDA margin declined 80bps YoY to 25% in Q2, with management guiding to lower end of 25-26% for full year. R&D increased 100bps, employee costs up 130bps, and GST-related stockist compensation impacted gross margins.
Analyst raised concern about chronic outperformance gap narrowing vs IPM over past several quarters. Management attributed this to price hike discipline (3.9% vs IPM 4.2%) and transformation disruptions, but acknowledged historical advantage may not sustain.
OTC revenue declined 3% YoY due to GST disruption and uneven monsoons, with primary sales impacted more than secondary sales (Manforce +14%, Gopex +36%). Recovery in H2 is expected but uncertain.